353 related articles for article (PubMed ID: 35205633)
1. Cannabidiol (CBD) in Cancer Management.
O'Brien K
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205633
[TBL] [Abstract][Full Text] [Related]
2. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
4. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
5. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
6. A validated method for the simultaneous quantification of cannabidiol, Δ
Kevin RC; Vogel R; Doohan P; Berger M; Amminger GP; McGregor IS
Drug Test Anal; 2021 Mar; 13(3):614-627. PubMed ID: 33095968
[TBL] [Abstract][Full Text] [Related]
7. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition.
Colizzi M; Ruggeri M; Bhattacharyya S
Front Psychol; 2020; 11():833. PubMed ID: 32528345
[TBL] [Abstract][Full Text] [Related]
9. Mid-infrared spectroscopy as process analytical technology tool for estimation of THC and CBD content in Cannabis flowers and extracts.
Geskovski N; Stefkov G; Gigopulu O; Stefov S; Huck CW; Makreski P
Spectrochim Acta A Mol Biomol Spectrosc; 2021 Apr; 251():119422. PubMed ID: 33477086
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Elmes MW; Kaczocha M; Berger WT; Leung K; Ralph BP; Wang L; Sweeney JM; Miyauchi JT; Tsirka SE; Ojima I; Deutsch DG
J Biol Chem; 2015 Apr; 290(14):8711-21. PubMed ID: 25666611
[TBL] [Abstract][Full Text] [Related]
11. Constituents of Cannabis Sativa.
Rock EM; Parker LA
Adv Exp Med Biol; 2021; 1264():1-13. PubMed ID: 33332000
[TBL] [Abstract][Full Text] [Related]
12. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
Hudson R; Renard J; Norris C; Rushlow WJ; Laviolette SR
J Neurosci; 2019 Oct; 39(44):8762-8777. PubMed ID: 31570536
[TBL] [Abstract][Full Text] [Related]
14. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
Szaflarski JP; Bebin EM
Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions.
Newton M; Newton DW
J Am Psychiatr Nurses Assoc; 2020; 26(5):447-457. PubMed ID: 32508204
[No Abstract] [Full Text] [Related]
16. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol: State of the art and new challenges for therapeutic applications.
Pisanti S; Malfitano AM; Ciaglia E; Lamberti A; Ranieri R; Cuomo G; Abate M; Faggiana G; Proto MC; Fiore D; Laezza C; Bifulco M
Pharmacol Ther; 2017 Jul; 175():133-150. PubMed ID: 28232276
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research.
McCartney D; Benson MJ; Desbrow B; Irwin C; Suraev A; McGregor IS
Sports Med Open; 2020 Jul; 6(1):27. PubMed ID: 32632671
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain.
Britch SC; Goodman AG; Wiley JL; Pondelick AM; Craft RM
J Pharmacol Exp Ther; 2020 Jun; 373(3):416-428. PubMed ID: 32179573
[TBL] [Abstract][Full Text] [Related]
20. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
